Diabetes continues to have a significant impact on morbidity and mortality in the United States, and is an ongoing treatment challenge for primary care providers who lack confidence with treatment intensification including newer agents and combination therapies resulting in clinical inertia. Further, approaches to improved adherence and lifestyle modification through shared-decision making continue to evolve with the goal of improving quality of care.
The expanded number of therapies with varying mechanisms of action for type 2 diabetes has resulted in novel combination regimens for patients not achieving goals despite therapy with metformin. Dr. Serge Jabbour will review novel combinations and approaches to intensifying therapy in this interactive case study.
This Expert Perspective highlights the salient points of the joint Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), published in 2012, on the management of hyperglycemia in type 2 diabetes.
This program will review the importance of timing and the benefit and barriers of initiating insulin in patients with type 2 diabetes. Various types of insulin will also be discussed including how to incorporate into clinical practice and how to use different types of insulin to optimize administration.
Primary care clinicians in the Southern United States face unique challenges in preventing and managing patients with T2DM. In this session, esteemed faulty will lend valuable insights into early screening and identification of those with pre-diabetes and T2DM in diverse patient populations, including minorities and the elderly. Earlier diagnosis offers the potential for reducing the risk for the development and progression of diabetes and associated complications.
With an ever-expanding array of antihyperglycemic options, pharmacologic management of T2DM can be challenging—but potentially more successful than ever. Learn about evidence-based clinical strategies that employ new classes of both oral and injectable antihyperglycemic agents and how one can individualize therapeutic approaches to best meet the needs of the patient. Additional insights will also be provided on how to interpret and use the latest guidelines and treatment algorithms to optimize therapy for your patients.
This enduring Interactive Exchange™ program translates published guidelines and the latest evidence on managing type 2 diabetes into practical, point-of-care recommendations. The case-based discussions focus on incretin-based therapies—notably, glucagon-like peptide (GLP)-1 receptor agonists—while exploring clinical approaches to maximize efficacy, ensure safety, and improve tolerability and treatment adherence.
The aim of this program is to review the impact of diabetes on eye health and how glycemic control contributes to diabetic eye disease. This program will also review treatment for diabetic eye disease and review referral and follow up plans for patients with diabetes to an appropriate eye specialist.
This activity reviews the latest data on the safety and efficacy of GLP-1 receptor agonists in the management of type 2 diabetes mellitus, utilizing case presentations to illustrate the application of theory to practice and incorporating the practical recommendations of leading clinicians in the treatment of these challenging patients.